FindTrial
Sign In

Velcade (bortezomib)

DRUG8 trials

Sponsors

Women and Infants Hospital of Rhode Island, European Society for Blood and Marrow Transplantation, Sidney Kimmel Cancer Center at Thomas Jefferson University, M.D. Anderson Cancer Center, Millennium Pharmaceuticals, Inc.

Conditions

Advanced CancerBrain CancerCentral Nervous System NeoplasmsCervical CancerCervix CancerHead and Neck CancerMultiple MyelomaMyeloma

Phase 1

A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
CompletedNCT00329589
Sidney Kimmel Cancer Center at Thomas Jefferson UniversityBrain Cancer, Central Nervous System Neoplasms, Cervix Cancer +1
Start: 2005-09-30End: 2010-06-30Updated: 2025-05-02
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
CompletedNCT00469209
M.D. Anderson Cancer CenterMyeloma
Start: 2006-06-30End: 2008-12-31Updated: 2020-09-24
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients
CompletedNCT00507442
Millennium Pharmaceuticals, Inc.Multiple Myeloma
Start: 2007-08-31End: 2010-11-30Updated: 2013-07-26
Study of Temsirolimus, Topotecan, and Bortezomib
CompletedNCT00770731
M.D. Anderson Cancer CenterAdvanced Cancer
Start: 2008-09-30End: 2012-11-30Updated: 2013-02-13

Phase 2

Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer
TerminatedNCT00106262
Women and Infants Hospital of Rhode IslandCervical Cancer
Start: 2005-03-31End: 2007-03-31Target: 38Updated: 2007-04-18
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
CompletedNCT00911859
Janssen Research & Development, LLCMultiple Myeloma
Start: 2009-06-30End: 2013-04-30Updated: 2014-11-18

Phase 3

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
TerminatedNCT00256776
European Society for Blood and Marrow TransplantationMultiple Myeloma
Start: 2005-07-31End: 2015-12-31Updated: 2021-10-18
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
CompletedNCT02136134
Janssen Research & Development, LLCMultiple Myeloma
Start: 2014-08-15End: 2024-01-10Updated: 2025-08-29

Related Papers

Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials.
2024-09-02
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
Blood Advances2023-12-049 citations
Pomalidomide, Dexamethasone, and Daratumumab Versus Other Triplet Regimens in Patients with Relapsed or Refractory Multiple Myeloma: A Population-Adjusted Indirect Treatment Comparison
Blood2023-11-02
P893: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS PHYSICIAN’S CHOICE THERAPY IN TRIPLE-CLASS EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHED COHORT ANALYSIS
HemaSphere2023-08-01
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology2022-11-22109 citations
Comparison of the Analytical Performance of EXENT®, a Mass Spectrometry-Based Assessment of M-Protein, to SPEP and NGS-Based MRD in Multiple Myeloma Patient Samples
Blood2022-11-157 citations
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
2022-07-223 citations
Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy.
Journal of Clinical Oncology2022-06-015 citations
B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
HemaSphere2022-04-01
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
2021-11-2520 citations
Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician's Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Blood2021-11-052 citations
Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
Blood2021-11-051 citations
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
European Journal Of Haematology2021-09-0811 citations
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Blood2021-07-2191 citations
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.
2020-09-0496 citations
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.
2020-08-2034 citations
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses
Advances in Therapy2020-02-2011 citations
PF596 EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D‐VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK
HemaSphere2019-06-01
Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.
Journal of Clinical Oncology2019-05-202 citations
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor
Blood2017-12-078 citations

11 more papers not shown